Statement of Changes in Beneficial Ownership (4)
January 11 2022 - 4:32PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
DEPTULA-HICKS DARLENE M |
2. Issuer Name and Ticker or Trading Symbol
F-star Therapeutics, Inc.
[
FSTX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Treasurer and CFO |
(Last)
(First)
(Middle)
C/O F-STAR THERAPEUTICS, INC., EDDEVA B920, BABRAHAM RESEARCH CAMPUS |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/9/2022 |
(Street)
CAMBRIDGE, X0 CB22 3AT
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | $4.77 | 1/9/2022 | | A | | 59823 (1) | | (2) | 1/9/2032 | Common Stock | 59823 | $0.00 | 59823 | D | |
Explanation of Responses: |
(1) | These options were granted under the Issuer's 2019 Equity Incentive Plan. |
(2) | Twenty five percent (25%) of the total number of shares under the award shall vest on the first anniversary of the Vesting Commencement Date, January 9, 2022, and thereafter in 36 equal monthly installments such that the stock option shall be fully-vested on the fourth annual anniversary of the Vesting Commencement Date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
DEPTULA-HICKS DARLENE M C/O F-STAR THERAPEUTICS, INC. EDDEVA B920, BABRAHAM RESEARCH CAMPUS CAMBRIDGE, X0 CB22 3AT |
|
| Treasurer and CFO |
|
Signatures
|
/s/ Darlene Deptula-Hicks | | 1/11/2022 |
**Signature of Reporting Person | Date |
F star Therapeutics (NASDAQ:FSTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
F star Therapeutics (NASDAQ:FSTX)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about F star Therapeutics Inc (NASDAQ): 0 recent articles
More F-star Therapeutics, Inc. News Articles